20 YEARS OF PROFESSIONAL & DEDICATED SERVICE TO GLOBAL CUSTOMERS

Custom Manufacturing, Project Outsourcing, your Trusted Partner from China

Progestogens and Meningioma Risk: A Closer Look at Desogestrel

The relationship between hormonal therapies and health outcomes is a complex area of ongoing medical research. Recently, studies have focused on the potential link between progestogen use, including Desogestrel, and the risk of developing intracranial meningiomas. NINGBO INNO PHARMCHEM CO.,LTD. provides high-quality Desogestrel to facilitate such critical research.

Meningiomas are typically benign tumors that arise from the meninges, the membranes surrounding the brain and spinal cord. While often slow-growing and non-cancerous, they can cause significant neurological symptoms if they press on vital structures. Previous research has indicated that certain progestogens may be associated with an increased risk of meningioma, particularly with prolonged use.

Recent large-scale studies have specifically investigated Desogestrel, a widely used progestogen in contraceptives and hormone therapies. These studies suggest a small increased risk of intracranial meningioma associated with the continuous use of Desogestrel for over five years. The research highlights that this risk appears to diminish and disappear approximately one year after discontinuation of the medication. Importantly, the studies found no similar increased risk associated with Levonorgestrel, another common progestogen.

Understanding the desogestrel pharmacology and its impact on the body is key to interpreting these findings. While the absolute risk remains low, these insights are crucial for informed clinical practice. Healthcare providers are advised to consider the duration of Desogestrel use and the individual patient's medical history when discussing contraceptive options or hormonal therapies. The continuous monitoring of desogestrel side effects and potential long-term risks is vital for ensuring patient safety.

NINGBO INNO PHARMCHEM CO.,LTD. remains committed to supporting the pharmaceutical industry by supplying reliable and high-purity Desogestrel. This commitment enables further research into its safety and efficacy, contributing to better patient outcomes and informed healthcare decisions.

Manufacturing Facilities

NINGBO INNO PHARMCHEM CO.,LTD. was established in 2007. It is committed to the R&D, production and sales of raw materials, pharmaceutical intermediates and fine chemicals. We striving to create a high-efficiency and high-quality integrated chemical service platform to better serve domestic and foreign customers.

Professional Export Experience

to Global Customers

WHY CHOSE US?

1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;

2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;

3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).

FAQ

  • A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.

  • A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.

  • A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.

CONTACT US
Should you need to contact us; you may call during regular business hours, Monday through Friday, 8am – 6 pm.
NINGBO INNO PHARMCHEM CO.,LTD.
Address: No.163 Ruiqing Rd.,Ningbo 315000 China
Phone: 86-574-87319282
Fax: 86-574-27912196
SEND US AN EMAIL

NAME*

EMAIL*

COMPANY

COUNTRY*

MESSAGE*

Previous: Navigating Desogestrel: From Chemical Synthesis to Patient Care

Next: The Crucial Role of Alpha-Ketoleucine Calcium in Modern Pharmaceutical Development

All Rights Reserved